IE
BTTX

Israel Englander’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Israel Englander’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-128,749
Closed -$25.1K – 6818
2023
Q4 		$25.1K Buy
128,749
+91,876
+249% +$20K ﹤0.01% 5598
2023
Q3 		$14.2K Buy
+36,873
New +$24.9K ﹤0.01% 5710
2023
Q2 		– Sell
-26,556
Closed -$19K – 6900
2023
Q1 		$19K Buy
26,556
+14,932
+128% +$17.5K ﹤0.01% 5881
2022
Q4 		$13K Sell
11,624
-2,632
-18% -$3.88K ﹤0.01% 6148
2022
Q3 		$25K Buy
+14,256
New +$26K ﹤0.01% 6408
2022
Q1 		– Sell
-68,310
Closed -$318K – 7718
2021
Q4 		$318K Sell
68,310
-22,221
-25% -$182K ﹤0.01% 5478
2021
Q3 		$903K Buy
90,531
+34,536
+62% +$344K ﹤0.01% 4801
2021
Q2 		$555K Buy
+55,995
New +$556K ﹤0.01% 5216

Other funds holding BTTX

CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Israel Englander's BTTX Position: Q1 2024 in Review

Israel Englander sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 128,749 shares — an estimated $25.1K sold.

Israel Englander first reported a position in BTTX in Q2 2021 and held it in 8 quarters. The position peaked at $903K in Q3 2021. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

  • Israel Englander reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Israel Englander sold 128,749 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $25.1K.
  • Israel Englander first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • Israel Englander's Better Therapeutics, Inc. Common Stock position peaked at $903K in Q3 2021.
  • 3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.